PBMCs from patients with MS have reduced levels of SHP-1 mRNA and protein (Christophi et al., 2008), due to increased DNA methylation of the SHP-1 promoter (Kumagai et al., 2012). This evidence concerns the gene PTPN6 and myeloid sarcoma.